Intellia co-founder Jean-François Formela retires from board, effective June 15

Intellia Therapeutics, Inc.

Jean-François Formela, co-founder and director since 2014, resigns from board effective June 15, 2023.
Resignation not due to any disagreement with Intellia on operations, policies, or practices.
Formela served on Audit and Compensation and Talent Development Committees.
No replacement was announced; board size will decrease upon his departure.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jean-François Formela

Director

NTLA · Intellia Therapeutics, Inc.

Effective: 2023-06-15
Filed: June 5, 2023, 7:59 PM ET

On June 5, 2023, Jean-François Formela notified Intellia Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective June 15, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jean-François Formela resigned as Director at Intellia Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On June 5, 2023, Jean-François Formela notified Intellia Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective June 15, 2023.

View on SEC.gov

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-160779

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.